705 Critical Quality Attribute Monitoring and Control in Pharmaceutical Manufacturing II


Description:
Developing robust pharmaceutical production processes to ensure patient safety and drug efficacy is dependent on the sound understanding and control of the drug substance and drug product quality attributes relevant for clinical performance and drug product manufacture. This understanding is then translated into the design of the manufacturing process and a relevant monitoring and control system to ensure that quality attributes within the desired ranges are consistently obtained. This session covers both drug substance and drug product critical quality attribute identification, characterization, and monitoring systems for quality and manufacturing process control. Authors are encouraged to highlight clinically relevant specifications for pharmaceutical products and innovative control strategies for drug substance and drug product manufacturing.

Sponsor:
Pharmaceutical Discovery, Development and Manufacturing Forum
Co-Sponsor(s):
Product Design (12G), Pharmaceuticals (15B)


Chair:
Huiquan Wu
Chemical Engineer
FDA/CDER
OPQ/OPF
LS64 Room 1080
Silver Spring, MD
20993
Phone Number: 3017960022
Fax Number: 301-796-9816
Email: huiquan.wu@fda.hhs.gov

Co-Chair:
Otute Akiti
Senior Director
Relypsa, Inc
Drug Substance Manufacturing & Development
Redwood City, CA
Phone Number: 650.421.9511
Fax Number: 650.421.9711
Email: oakiti@relypsa.com


Papers:
Routine Process Monitoring for Automated Clean-in-Place Systems
Juan C. Silva-Martinez, Lilly- Puerto Rico
Scientific Considerations and Regulatory Challenges for Low Dose Drug Manufacturing Process Monitoring and Control
Huiquan Wu, FDA CDER OPQ; Suyang Wu, FDA CDER OPQ; Koushik Sowrirajan, FDA; Celia N. Cruz, U.S. Food and Drug Administration
Frontiers of Industrial Crystallization Science and Technology
Junbo Gong, Tianjin University; Jingkang Wang, National Engineering Research Center for Industrial Crystallization Technology, School of Chemical Engineering and Technology, Tianjin University
Self-Aggregation of Gabapentin Under Confinement of Primary Particle By Smpt
Songgu Wu, Tianjin University; Junbo Gong, Tianjin University
Feasibility of NIR Spectroscopy for Monitoring Enzymic Digestion Process of Proinsulin Producing Insulin Glargine
Xu Yan, Zhejiang University; Lei Nie, Zhejiang University; Sheng Zhang, Zhejiang University; Weiming Wang, Zhejiang Hisun Pharmaceutical CO., LTD; Haibin Wang, Zhejiang Hisun Pharmaceutical CO., LTD; Wenlong Li, Zhejiang University; Haibin Qu, Zhejiang University
Abstract Submissions Closed